文献速递心脑血管急症

多中心队列中胸痛患者心脏检查率的种族差异

Race differences in cardiac testing rates for patients with chest pain in a multisite cohort.
PubMed 文献 · Acad Emerg Med · 2023-06-19
一句话结论美国8个急诊科的前瞻性队列显示,非白人胸痛患者30天接受无创检查和心导管检查的几率低于白人,但血运重建和心性死亡或心肌梗死率相似。

该研究为STOP-CP前瞻性队列的二次分析,纳入2017至2018年美国8个急诊科1454例疑似急性冠脉综合征且无ST段抬高的成人。30天无创检查率31.4%,心导管检查率13.5%,血运重建率6.0%,心性死亡或心肌梗死率13.1%。白人 vs 非白人无创检查率33.8% vs 28.1%(OR 0.76,95%CI 0.61-0.96),心导管检查率15.9% vs 10.4%(OR 0.62,95%CI 0.45-0.84),校正后仍相关(aOR 0.71,95%CI 0.56-0.90;aOR 0.62,95%CI 0.43-0.88)。血运重建和心性死亡或心肌梗死率无显著差异。

要点

  • 非白人患者30天无创检查率低于白人(28.1% vs 33.8%,OR 0.76,95%CI 0.61-0.96),校正后仍低(aOR 0.71,95%CI 0.56-0.90)。
  • 非白人患者30天心导管检查率低于白人(10.4% vs 15.9%,OR 0.62,95%CI 0.45-0.84),校正后仍低(aOR 0.62,95%CI 0.43-0.88)。
  • 血运重建率白人6.9% vs 非白人4.7%(OR 0.67,95%CI 0.42-1.04),校正后无关联(aOR 0.74,95%CI 0.45-1.20)。
  • 30天心性死亡或心肌梗死率白人14.2% vs 非白人11.5%(OR 0.79,95%CI 0.57-1.08),校正后无关联(aOR 0.74,95%CI 0.50-1.09)。

适用人群与场景

  • 美国8个急诊科前瞻性纳入的成人,有提示急性冠脉综合征的症状且无ST段抬高,2017至2018年。

研究设计与关键结果

  • 研究类型:STOP-CP前瞻性队列的二次分析,纳入1454例参与者,42.3%(615/1454)为非白人。
  • 30天结局:无创检查31.4%(457/1454),心导管检查13.5%(197/1454),血运重建6.0%(87/1454),心性死亡或心肌梗死13.1%(190/1454)。
  • 白人 vs 非白人:无创检查33.8%(284/839) vs 28.1%(173/615),OR 0.76(95%CI 0.61-0.96);校正后aOR 0.71(95%CI 0.56-0.90)。
  • 白人 vs 非白人:心导管检查15.9%(133/839) vs 10.4%(64/615),OR 0.62(95%CI 0.45-0.84);校正后aOR 0.62(95%CI 0.43-0.88)。
  • 白人 vs 非白人:血运重建6.9%(58/839) vs 4.7%(29/615),OR 0.67(95%CI 0.42-1.04);校正后aOR 0.74(95%CI 0.45-1.20)。
  • 白人 vs 非白人:30天心性死亡或心肌梗死14.2%(119/839) vs 11.5%(71/615),OR 0.79(95%CI 0.57-1.08);校正后aOR 0.74(95%CI 0.50-1.09)。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示急诊胸痛评估中非白人患者接受无创检查和心导管检查的几率较低,但校正后血运重建和心性死亡或心肌梗死率无显著差异,原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Identifying and eliminating racial health care disparities is a public health priority. However, data evaluating race differences in emergency department (ED) chest pain care are limited.

METHODS: We conducted a secondary analysis of the High-Sensitivity Cardiac Troponin T to Optimize Chest Pain Risk Stratification (STOP-CP) cohort, which prospectively enrolled adults with symptoms suggestive of acute coronary syndrome without ST-elevation from eight EDs in the United States from 2017 to 2018. Race was self-reported by patients and abstracted from health records. Rates of 30-day noninvasive testing (NIT), cardiac catheterization, revascularization, and adjudicated cardiac death or myocardial infarction (MI) were determined. Logistic regression was used to evaluate the association between race and 30-day outcomes with and without adjustment for potential confounders.

RESULTS: Among 1454 participants, 42.3% (615/1454) were non-White. At 30 days NIT occurred in 31.4% (457/1454), cardiac catheterization in 13.5% (197/1454), revascularization in 6.0% (87/1454), and cardiac death or MI in 13.1% (190/1454). Among Whites versus non-Whites, NIT occurred in 33.8% (284/839) versus 28.1% (173/615; odds ratio [OR] 0.76, 95% confidence interval [CI] 0.61-0.96) and catheterization in 15.9% (133/839) versus 10.4% (64/615; OR 0.62, 95% CI 0.45-0.84). After covariates were adjusted for, non-White race remained associated with decreased 30-day NIT (adjusted OR [aOR] 0.71, 95% CI 0.56-0.90) and cardiac catheterization (aOR 0.62, 95% CI 0.43-0.88). Revascularization occurred in 6.9% (58/839) of Whites versus 4.7% (29/615) of non-Whites (OR 0.67, 95% CI 0.42-1.04). Cardiac death or MI at 30 days occurred in 14.2% of Whites (119/839) versus 11.5% (71/615) of non-Whites (OR 0.79 95% CI 0.57-1.08). After adjustment there was still no association between race and 30-day revascularization (aOR 0.74, 95% CI 0.45-1.20) or cardiac death or MI (aOR 0.74, 95% CI 0.50-1.09).

CONCLUSIONS: In this U.S. cohort, non-White patients were less likely to receive NIT and cardiac catheterization compared to Whites but had similar rates of revascularization and cardiac death or MI.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Popp LM, Ashburn NP, Snavely AC, et al. Race differences in cardiac testing rates for patients with chest pain in a multisite cohort. Acad Emerg Med. 2023. PMID: 37306075. doi:10.1111/acem.14762

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。